Board of Directors

GlycoMimetics board members possess a broad and deep range of experience in varied business, financial, scientific, medical and multinational sectors of the life sciences. Our Board works closely with our Management Team to drive the success of our programs.

M. James Barrett, Ph.D., Chairman of the Board of Directors

Dr. Barrett joined venture capital firm New Enterprise Associates (NEA), in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships in addition to GlycoMimetics include Amicus Therapeutics (NASDAQ:FOLD), Clovis Oncology (NASDAQ:CLVS), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), and Targacept, Inc. (NASDAQ: TRGT). Dr. Barrett also sits on the board of several private companies. Prior to NEA, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 – 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 – 1995), President and CEO of Life Technologies (1985 – 1987), and President and CEO of Bethesda Research Labs (1982 – 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.

Back to top

John J. Baldwin, Ph.D., Director

Dr. Baldwin co-founded Hua Medicine in 2010 and is a member of the Board of Directors. In 2001 he co-founded Vitae Pharamaceuticals, Inc.  where he served as the company’s President and Chief Scientific Officer. Prior to that, he spent nine years at Pharmacopeia, Inc., where he was a co-founder and served as Chief Scientific and Technology Officer. During this period, he co-founded WuXi PharmaTech, a research and development service company located in China, and served on its Board of Directors. Prior to Pharmacopeia, Dr. Baldwin was a Distinguished Senior Scientist at Merck & Co., where he spent 33 years in various scientific and management positions.

Back to top

Michael Henos, Director

Mr. Henos is the founder and Managing General Partner of Alliance Technology Ventures, L.P. (“ATV”), a venture capital firm based in the Southeast. Prior to founding ATV in 1993, Mr. Henos served as a General Partner of Aspen Ventures, a venture capital fund, and as a Vice President with 3i Ventures, the predecessor fund to Aspen during the period from 1986 to 1993. Mr. Henos has extensive experience as a venture capital investor and as a current and past director of various public and privately held biopharmaceutical companies. He more recently has served as a director of Genoptix, Inc., Atherogenics, Inc., and Inhibitex, Inc., all publicly held biopharmaceutical companies.  Mr. Henos was Chairman of the Board for both Atherogenics and Inhibitex and also served as their compensation committee chairs. Prior to venture capital investing, Mr. Henos held operating positions with Science Applications Inc, Revlon Healthcare Group and Pro-med Technologies, which he co-founded.  Mr. Henos received a B.S. in Economics and a M.B.A. in Finance from the University of California, Los Angeles.

Back to top

Rachel K. King, Chief Executive Officer

Back to top

John Magnani, Ph.D., Vice President and Chief Scientific Officer

Back to top

Timothy R. Pearson, Director

Mr. Pearson most recently held the position of Chief Financial Officer, Executive Vice President and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. Prior to joining Catalyst Health Solutions, Mr. Pearson served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune’s Executive Team. Mr. Pearson joined MedImmune in 1998 and prior to the acquisition by AstraZeneca and his promotion to CFO in 2007, was Vice President of Finance and Treasurer with responsibility for treasury, corporate finance, tax, risk management, Sarbanes-Oxley compliance, internal audit and equity plan administration. During his tenure at MedImmune, Mr. Pearson was a key leader in a number of MedImmune’s financing and M&A transactions, including its $500 million acquisition of U.S. Bioscience and its $1.6 billion acquisition of Aviron, as well as related post acquisition integration efforts. Mr. Pearson was a founding officer and investment committee member of MedImmune Ventures, MedImmune’s venture capital fund that invests in early-stage biotechnology companies. Prior to MedImmune, Mr. Pearson held various financial roles of increasing responsibility at Integrated Health Services, CIGNA Insurance and First National Bank of Maryland.  Mr. Pearson, a Certified Public Accountant, holds dual Bachelor of Science degrees in Business Administration from the University of Delaware and Accounting from the University of Maryland University College, as well as a Master of Science degree in Finance from Loyola University.

Back to top

Franklin H. Top, Jr., M.D., Director

Dr. Top joined MedImmune in June 1988 as Executive Vice President and was a member of its Board of Directors from 1988 through 2004. He became MedImmune’s Medical Director in 1990. From 2004 to 2010, Dr. Top served as Senior Vice President in MedImmune, LLC’s venture capital affiliate, MedImmune Ventures Inc. From 1987 to 1988, Dr. Top served as Senior Vice President for Clinical and Regulatory Affairs at Praxis Biologics. Prior to 1987, Dr. Top served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director and Commandant, Walter Reed Army Institute of Research in 1983.

Back to top